Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,082.99
(
-0.37%
)
US TECH 100
25,836.80
(
-0.13%
)
Dow Jones
49,246.99
(
-0.41%
)
Brent Oil
96.61
(
6.54%
)
Bitcoin
74,995.47
(
-1.18%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

masterlongevity

Send PM Follow Ignore
Followers 24
Posts 2597
Boards Moderated 0
Alias Born 01/07/2004

masterlongevity

Re: DewDiligence post# 145458

Saturday, 07/14/2012 2:31:39 PM

Saturday, July 14, 2012 2:31:39 PM

Post# of 257432
the ph 1 data looks great. I have heard that they will be going straight to a ph2/3 in Mild cognitive impairment, which i think is very smart. No other amyloid therapy should ever be tested on mild to moderate AD patients. 10+ trial failures is enough, and especially if bapi and solanezumab fail
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today